Non-Invasive, MultiOmic and MultiCompartmental Biomarkers of Reflux Disease: A Systematic Review

Muhammad S. Farooqi; Sanjiti Podury; George Crowley; Sophia Kwon; Abraham R. Khan; Fritz Francois; Anna Nolan

doi:10.1101/2022.06.20.22276215

ABSTRACT

Background and Aims Gastroesophageal reflux disease (GERD) is a prevalent GI disorder which may complicate conditions such as obstructive airways disease (OAD). Our group has identified predictive biomarkers of GERD in particulate exposed 1^st responders with OAD. Additionally, GERD diagnosis and treatment is costly, and invasive. In light of these clinical concerns our aim was to systematically review studies identifying non-invasive, multiOmic and multi-compartmental biomarkers of GERD.

Methods A systematic review of PubMed and EMBASE was performed on February 22, 2022 utilizing keywords focusing on reflux disease and biomarkers. The study was registered with PROSPERO (2022-CRD42022301543). We included: original human studies in English, published after December 31, 2009 focusing on non-invasive biomarkers of GERD. Reflux related conditions included Nonerosive Reflux Disease (NERD) Laryngopharyngeal Disease (LPR), Erosive Esophagitis (EE) and Barretts Esophagus (BE). Predictive measures were synthesized and bias assessed.

Results Primary search identified 241 studies. After removing duplicates and applying inclusion/exclusion criteria n=15 articles were identified. Salivary pepsin was the most studied biomarker (n=5) with a significant sensitivity and specificity for GERD and LPR detection. Studies showed that for GERD diagnosis, miR-203 downregulation had the highest area under curve the receiver operator curve(ROC_AUC) 0.94(95% CI; 0.90-0.7). An oral microbiome model including Lautropia, Streptococcus and Bacteroidetes showed the greatest discrimination between BE and controls vs Lautropia alone; sensitivity of 96.9%, specificity of 88.2% and ROC_AUC of 0.94(0.81-1.00).

Conclusion Prior studies identified significant multiOmic, multi-compartmental non-invasive biomarker risks for GERD and its complications such as BE. However, due to study limitations and to further ascertain the reliability and accuracy of these biomarkers more studies are warranted.

BACKGROUND Gastroesophageal reflux disease (GERD) is a prevalent GI disorder which may complicate conditions such as obstructive airways disease (OAD). GERD diagnosis and treatment is costly, and invasive. In light of these clinical concerns our aim was to systematically review studies identifying non-invasive, multiOmic and multi-compartmental biomarkers of GERD.

FINDINGS Salivary pepsin was the most studied biomarker with a significant sensitivity and specificity for GERD detection. Studies showed that for GERD diagnosis, miR-203 downregulation had the highest ROC_AUC. An oral microbiome model including Lautropia, Streptococcus and Bacteroidetes showed the greatest discrimination between Barrette’s Esophagus and controls vs Lautropia alone.

IMPLICATIONS FOR PATIENT CARE Prior studies identified significant multiOmic, multi-compartmental non-invasive biomarker risks for GERD and its complications such as BE. However, due to study limitations and to further ascertain the reliability, accuracy and clinical utility of these biomarkers more studies are warranted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

CDC/NIOSH U01-(OH012069, OH011300, OH011855); NHLBI R01HL119326. The funding agencies did not participate in the study design; collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Guarantor of the Article. Anna Nolan accepts full responsibility for the conduct of the study. She has access to the data and has control of the decision to publish.
Grant Support. CDC/NIOSH U01-(OH012069, OH011300, OH011855); NHLBI R01HL119326. The funding agencies did not participate in the study design; collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Disclosures/Potential Competing Interests: There are no potential or actual conflicts of interest reported by any of the authors. The views expressed in this article do not communicate an official position of the institution, or funding source.
Data Transparency Statement— All data produced in the present work are contained in the manuscript